May 08, 2022 – Umbralisib (Ukoniq) is a medication for the treatment of marginal zone lymphoma (MZL) and follicular lymphoma (FL). Umbralisib (Ukoniq) inhibits multiple kinases. In biochemical and cell-based assays, Umbralisib inhibited PI3Kδ and casein kinase CK1ε. PI3Kδ is expressed in …

Umbralisib (Ukoniq): Drug recall because increased risk of patient death Read more »

April 27, 2010 – From an announcement by the EMEA we learn that bufexamac-containing medicines were to be taken off EU markets because of high risk of contact allergies. The European Medicines Agency’s Committee for Medicinal Products for Human Use …

European Medicines Agency (EMEA) recommends revocation of marketing authorisation for bufexamac containing medicines. Read more »

December 31, 2009 – The European Medicines Agency (EMEA) has recommended the withdrawal of all medicines containing Benfluorex in the European Union, because their risks, particularly the risk of heart valve disease, are greater than their benefits. Doctors should stop …

European Medicines Agency (EMEA) recommends withdrawal of Benfluorex from the market in European Union Read more »